Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299105 | 0.87 | FGFR1 (0.60) | SMN1; SMN2ALDH1A1KDM4EBRD4BRPF1 | |
| SCHEMBL1869730 | 0.85 | FGFR1 (0.60) | SMN1; SMN2ALDH1A1HSD17B10FGFR1DYRK1A | |
| SCHEMBL16602284 | 0.85 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1FGFR1DYRK1ACHRNA7 | |
| SCHEMBL29819602 | 0.85 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1FGFR1DYRK1ACHRNA7 | |
| SCHEMBL20570515 | 0.83 | CHRNA7 (0.47) | SMN1; SMN2ALDH1A1FGFR1DYRK1ACHRNA7 | |
| SCHEMBL7362182 | 0.83 | F10 (0.49) | SMN1; SMN2DYRK1ACHRNA7KMT2ANPC1 | |
| SCHEMBL3491023 | 0.83 | CHRNA7 (0.53) | SMN1; SMN2ALDH1A1KDM4EFGFR1DYRK1A | |
| Carbamic Acid SCHEMBL3412931 | 0.82 | ALDH1A1 (0.50) | SMN1; SMN2ALDH1A1KDM4EFGFR1DYRK1A | |
| SCHEMBL18229473 | 0.81 | FGFR1 (0.50) | SMN1; SMN2ALDH1A1KDM4EBRD4BRPF1 | |
| SCHEMBL3492748 | 0.81 | FGFR1 (0.53) | SMN1; SMN2ALDH1A1KDM4EFGFR1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| EP-4536656-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2024263963-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING HEAD AND NECK CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-4398904-A1 | SELECTED COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 | C4 Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024105144-A1 | QUINAZOLINONE COMPOUND AS BRAF INHIBITOR FOR THE TREATMENT OF ADVANCED SOLID CANCER OR METASTASES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-116723839-A | Tricyclic heterobifunctional compounds for degrading target proteins | C4医药公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-4228625-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4228639-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4228624-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2019191112-A1 | CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS | C4 THERAPEUTICS, INC. (US) | 2019-10-03 | — | — | WO | disclosed |
| WO-2018237026-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2018-12-27 | — | — | WO | disclosed |
| WO-2018209155-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2018-11-15 | — | — | WO | disclosed |
| EP-3373978-A1 | AGGREGATING MICROPARTICLES FOR THERAPY | Graybug Vision, Inc. (US) | 2018-09-19 | — | — | EP | disclosed |
| WO-2017083779-A1 | AGGREGATING MICROPARTICLES FOR THERAPY | Graybug Vision, Inc. (US) | 2017-05-18 | — | — | WO | disclosed |
| EP-2791101-A1 | TREATMENT OF INFLAMMATION | Vascular Biogenics Ltd. (IL) | 2014-10-22 | — | — | EP | disclosed |
| WO-2014074805-A1 | SELECTIVE TARGETING OF CANCER STEM CELLS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-05-15 | — | — | WO | disclosed |
| WO-2013088245-A1 | TREATMENT OF INFLAMMATION | VASCULAR BIOGENICS LTD. (IL) | 2013-06-20 | — | — | WO | disclosed |
| EP-2493310-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011056635-A1 | BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | KIT, CTSL, PAICS | SMN1; SMN2 4104/4885ALDH1A1 1779/4885KDM4E 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.